Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
Commits to plant 5000 trees in phase 1 with its partner SankalpTaru Foundation
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
A simple blood test detects over 30 types of cancers
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Subscribe To Our Newsletter & Stay Updated
